Gencove

In-depth sequencing requires huge amounts of time, and sequencing methods are classically either comprehensive and slow, or swift but limited. Gencove’s technology combines low-pass whole genome sequencing, which reads the DNA fewer times, with a computation layer, to provide a complete set of genomic information with an attainable price tag. By focussing on software over hardware, which has traditionally been at the root of genomic advancements, Gencove has found a way to catch the eye of companies who want to make the most of sequencing data.

Gencove is trusted by leading plant and animal companies, academic institutions such as Harvard and Oxford, biotechnology, diagnostic, genomics, and pharma companies. With its 2021 funding Gencove is embarking on further product development, growing commercially, and building out key functions in the business.